From Pilot to Production: Why Most Healthcare AI Stalls, and What Works

There is a familiar arc in healthcare AI. A pilot launches with enthusiasm, the early metrics look encouraging, a case study gets written, and then the project quietly fails to scale. The technology was not the problem; the pilot worked. What broke was the path from a contained experiment to something that runs every day across the organization. Having backed and operated services businesses through plenty of technology rollouts, we have come to treat the pilot-to-production gap as the central risk in this category, and as the place where the real diligence happens.

Why Pilots Flatter the Technology

Pilots are designed to succeed. They run with a motivated team, clean data, a narrow scope, and leadership attention. None of those conditions survive contact with full deployment. The enthusiastic early adopters are not representative of the median user. The curated data is cleaner than what the model meets in production. And the executive sponsor who cleared obstacles for the pilot is not there to clear them for the twentieth site.

So the first thing we do is discount the pilot. A good pilot tells you the technology can work under favorable conditions. It tells you almost nothing about whether the business can make it work under normal ones. The interesting question is what happens at the boundary between the two.

The Real Barriers Are Not Technical

When deployments stall, the cause is rarely the model. It is some combination of integration, workflow, trust, data, and regulation, and these compound.

Integration is the most common killer. A tool that does not write back into the EHR or the existing system of record forces staff to work in two places at once, and the time savings evaporate. Workflow is next: a tool that asks clinicians or billers to change how they work, without an obvious payoff to them personally, gets routed around. Trust matters in healthcare more than almost anywhere; a model that produces a few visible errors early loses credibility that is expensive to rebuild, and quiet non-adoption follows.

Data is the barrier that surprises people. The model that performed well on one organization's historical data often degrades on another's, because documentation habits, patient mix, and source-system quirks differ. And regulation and procurement add friction at every step, from privacy and security review to clinical governance to the simple reality that healthcare buying cycles are long and involve many stakeholders who can each say no.

What Separates the Deployments That Scale

The businesses that cross the gap tend to share a set of habits, and they are operational habits more than technical ones.

They integrate deeply and early, treating the EHR and system-of-record connection as the product, not an afterthought. They design for the median user and the messy case, not the enthusiastic pilot participant. They keep a human in the loop where stakes are high, which builds the trust that drives adoption rather than undermining it. They invest in implementation and change management as a discipline, with real people who sit with customers through go-live, because adoption is a service, not a download. And they measure themselves on outcomes the customer already tracks, so value is provable in the customer's own language.

Crucially, the ones that scale also plan for model maintenance. Payer rules change, clinical guidelines change, documentation patterns drift. A model is a perishable asset. The businesses that treat monitoring and retraining as an ongoing operating cost, rather than assuming a one-time install, are the ones whose results hold up over years instead of quarters.

How We Diligence It

When we look at an AI-enabled healthcare business, the pilot deck is the least interesting document in the room. We want to see deployments that have been live long enough to reveal whether usage persists. We ask about the gap between pilot results and production results, because a vendor who can talk candidly about that gap usually understands their own business. We look at implementation: how long go-live takes, how much hand-holding it requires, and whether that cost is trending down as the company gets repetitions. And we look at retention and expansion within existing customers, because a tool that scales inside an account is one that survived the production transition; a flat or churning base is a tool that stalled.

The Kiron Take

Healthcare AI does not have a technology problem nearly as much as it has an adoption problem. The pilot proves the science; production proves the business. We put our weight on the second, because that is where value is actually created and where most of the failures hide. The companies worth backing are the ones that have treated integration, workflow, trust, and ongoing model upkeep as the hard core of the work, and have the live, persistent usage to show for it. Everyone can run a pilot. Far fewer can run in production, and that scarcity is exactly where the opportunity sits.